Is Bristol-Myers Squibb Company (BMY) a Buy, Sell, or Hold?
Bristol-Myers Squibb Company
NYSE:BMY
$56.95 USD
-$2.39 (-4.03%)
- Volume
- 10.84M
- Average Volume
- 11.48M
- Market Capitalization
- $116.3B
- P/E Ratio
- 16.00
- Dividend Yield
- 4.41%
- Price Target
- $65.00
- Year High
- $62.89
- Year Low
- $42.52
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.70
- Current Ratio
- $1.42
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Christopher S. Boerner |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | BMY |
| CUSIP | 110122108 |
| CIK | 0000014272 |
| Web | https://www.bms.com |
| Phone | 609 252 4621 |
| Currency | USD |
| Employees | 32500 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.22 |
| Payout Ratio | 0.70 |
| Current Ratio | 1.42 |
| Quick Ratio | 1.28 |
| Cash Ratio | 0.50 |
Sales & Book Value
| Annual Sales | $48.19B |
| Price / Sales | 2.40 |
| Cash Flow | 5.83 |
| Price / Cash Flow | 9.77 |
| Price / Book | 5.80 |
Price Target and Rating
| Average Stock Price Forecast | $65.00 |
| High Stock Price Forecast | $75.00 |
| Low Stock Price Forecast | $40.00 |
| Forecast Upside/Downside | -12.38% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 41 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $3.45 |
| Trailing P/E Ratio | 16.00 |
| PEG Ratio | 0.49 |
| P/E Growth | 0.49 |
| Net Income | $7.05B |
| Net Margin | 15.01% |
| Pretax Margin | 19.79% |
| Return on Equity | 39.05% |
| Return on Assets | 8.41% |
Financials Score
| AltmanZ Score | 2.46 |
| Piotroski Score | 8.00 |
| Working Capital | 8.05B |
| Total Assets | 86.48B |
| Ebit | 10.46B |
| Market Cap | 121.18B |
| Total Liabilities | 66.37B |
Poll Results
About Bristol-Myers Squibb Company (NYSE:BMY) Stock
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for mul ... tiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
Can BMY's CELMoD Program Advancements Strengthen Its Oncology Portfolio?
2026-07-14 10:56:35
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
2026-07-14 05:00:00
Voluntary pricing deals reduce uncertainty for major drugmakers. Drug pricing pressure won't affect every pharmaceutical company equally.
Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment
2026-07-13 14:00:36
The U.S. Food and Drug Administration (FDA) on Monday accepted the new drug application for Bristol Myers Squibb & Co.'s (NYSE:BMY) investigational oral therapy mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma.
2026-07-13 06:59:00
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--U.S. FDA Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma.
Start Investing At 60 And Retire On Dividends Forever
2026-07-10 08:00:00
Retiring on dividends remains achievable for late starters by building a high-yield, quality portfolio targeting a 6% yield with safe, growing payouts. Dividend-focused strategies mitigate sequence of returns risk, enabling investors to live off income rather than depleting principal during market downturns. Examples like Enbridge Inc. (ENB), Omega Healthcare Investors, Inc. (OHI), and Bristol-Myers Squibb Company (BMY) illustrate our buy low, sell high, and get paid to wait principles, delivering strong returns and dividend growth.
2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now
2026-07-07 18:30:00
They may not remain cheap for too much longer.
3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)
2026-07-07 10:45:00
AbbVie is hitting its stride now that it has transitioned past Humira's patent expiration. Medtronic is a steady dividend payer with some intriguing upside in robotics-assisted surgery.
Is Bristol Myers Squibb's 4.3% Dividend Yield Safe? Here's What Investors Need to Know.
2026-07-06 04:44:00
Bristol Myers Squibb is generating more than enough earnings to cover its dividend right now. However, the company faces a daunting patent cliff.
Frequently Asked Questions
-
What is the current Bristol-Myers Squibb Company (BMY) stock price?
-
Bristol-Myers Squibb Company(NYSE:BMY) stock price is $56.95 in the last trading session. During the trading session, BMY stock reached the peak price of $62.89 while $42.52 was the lowest point it dropped to. The percentage change in BMY stock occurred in the recent session was --4.03% while the dollar amount for the price change in BMY stock was -$-2.39.
-
BMY's industry and sector of operation?
-
The NYSE listed BMY is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of BMY?
-
Adam Lenkowsky | Executive Vice President & Chief Commercialization Officer
Cristian Massacesi | Executive Vice President, Chief Medical Officer & Head of Development
Greg Meyers | Executive Vice President and Chief Digital & Technology Officer
Ahn Amanda Poole | Executive Vice President & Chief People Officer
Cari Gallman | Executive Vice President, General Counsel & Chief Policy Officer -
How many employees does BMY have?
-
Number of BMY employees currently stands at 32500. BMY operates from Route 206 & Province Line Road, Princeton, NJ 08543, US.
-
Link for BMY official website?
-
Official Website of BMY is: https://www.bms.com
-
How do I contact BMY?
-
BMY could be contacted at phone #609 252 4621 and can also be accessed through its website. BMY operates from Route 206 & Province Line Road, Princeton, NJ 08543, US.
-
How many shares of BMY are traded daily?
-
The average number of BMY shares traded daily for last 3 months was 11.48M.
-
What is the market cap of BMY currently?
-
The market value of BMY currently stands at $116.3B with its latest stock price at $56.95